- Zacks
has reiterated support for their initial $4.44 share price target for
Pressure BioSciences
- PBIO’s
fundamentals remain strong, with record sales of consumables and increased
revenue from products and services over same quarter previous year
- Company
anticipates doubling of total revenue in 2020, driven by anticipated sales
of their proprietary BaroShear K45 System, which provides the CBD market
with much-needed, superior water-soluble nanoemulsions of CBD Oil
Zacks Small Cap Research, a division of Zacks Investment
Research, has announced that they are maintaining their strong $4.44 share
price target originally stated in their initial coverage of Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
sale and development of pressure-based consumables, instruments, and platform
technology solutions to the global life sciences industry. PBIO’S unique and
enabling pressure platform technologies can be used in many large and growing
markets (e.g., food preservation, medical/lab applications, and, importantly,
CBD oil water solubility).
The Zacks report (http://ibn.fm/z1W3H) points to demand that “is expected to
accelerate starting in 2020,” which nonetheless follows many years of
consistent yearly revenue increases by PBIO. The company itself is standing by
its stated anticipation of doubling revenue in 2020, due to expected sales of
their soon-to-be-released $200,000 BaroShear K45 systems. These new instrument
systems utilize PBI’s proprietary Ultra Shear Technology™ (UST) platform to
effectively produce high quality, long-term stable, water-soluble nanoemulsions
of CBD Oil (http://ibn.fm/PFora).
True water-soluble CBD is now seen as critical to the CBD
market, since water-solubility is necessary for bioavailability. It also allows
for accurate dosing for consumers, something that has been sorely missing
up to now. Without accurate dosing, you can’t really control the amount of
CBD that actually gets into the bloodstream and available by the consumer. In
essence, it doesn’t matter how organic or potent a company says their CBD is,
if it is not truly water soluble then it is not going to be properly absorbed
by the body and will be largely excreted. PBIO’s revolutionary, patented, and
highly anticipated UST-based BaroShear K45 system is expected to provide
superior water-solubility, long-term shelf stability, improved safety, and
significantly increased bio-availability compared to current nanoemulsification
methods, overcoming key weaknesses of the other approaches.
The BaroShear K45 features a unique, highly efficient,
customized ultra-high pressure (UHP) subsystem generating pressure levels of up
to 45,000 psi. The system’s maximum throughput capacity is one liter per eight
hours. The platform is also suitable for processing small volumes (e. g., min.
20 ml) of high-quality CBD oil into a water-soluble nanoemulsion with minimal
production loss.
To view the full Zacks report, visit http://ibn.fm/z1W3H
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
